Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 22, 2007
Last updated: September 27, 2012
Last verified: September 2012
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Condition Intervention Phase
Dyslipidemia, Renal Insufficiency
Drug: ABT-335
Drug: Rosuvastatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetics of ABT-335 and Rosuvastatin in Subjects With Normal Renal Function and Renal Impairment

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Blood concentrations of the active ingredients and metabolites of ABT-335 and rosuvastatin [ Time Frame: Days 1, 8, 9, and 10 ]

Secondary Outcome Measures:
  • Safety and tolerability of the study drugs [ Time Frame: Study duration ]

Enrollment: 37
Study Start Date: January 2008
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ABT-335
45 mg once daily for 10 consecutive days
Drug: Rosuvastatin
10 mg once daily for 10 days


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Body Mass Index (BMI) 19 to 33, inclusive

Either normal kidney function, or mild or moderate kidney impairment

Exclusion Criteria

Use of any medications, vitamins and/or herbal supplements within 2 weeks prior to study drug administration, except those required for management of renal disease.

History of epilepsy, any clinically significant cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00585143

United States, Florida
Site Reference ID/Investigator# 6610
Gainesville, Florida, United States, 32608
Site Reference ID/Investigator# 6738
Miami, Florida, United States, 33136
United States, Minnesota
Site Reference ID/Investigator# 7723
Minneapolis, Minnesota, United States, 55404
United States, Tennessee
Site Reference ID/Investigator# 7319
Knoxville, Tennessee, United States, 37920
United States, Texas
Site Reference ID/Investigator# 6928
San Antonio, Texas, United States, 78209
United States, Virginia
Site Reference ID/Investigator# 8280
Richmond, Virginia, United States, 23298-0160
Sponsors and Collaborators
Study Director: Torbjörn Lundström, MD AstraZeneca
  More Information

Responsible Party: AstraZeneca Identifier: NCT00585143     History of Changes
Other Study ID Numbers: M10-070
Study First Received: December 22, 2007
Last Updated: September 27, 2012

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Renal Insufficiency
Lipid Metabolism Disorders
Metabolic Diseases
Kidney Diseases
Urologic Diseases
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on May 24, 2017